These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 7215100)
21. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325 [TBL] [Abstract][Full Text] [Related]
22. Incontinence of urine with long-term bromocriptine therapy. Gopinathan G; Calne DB Ann Neurol; 1980 Aug; 8(2):204. PubMed ID: 6775584 [No Abstract] [Full Text] [Related]
28. [Pleuro-pulmonary changes after bromocriptine treatment of parkinsonism]. Bøttcher J; Grøn U Ugeskr Laeger; 1981 Oct; 143(41):2648-9. PubMed ID: 7303288 [No Abstract] [Full Text] [Related]
29. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. Montastruc JL; Schmitt L; Bagheri H Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874 [TBL] [Abstract][Full Text] [Related]
30. Bromocriptine and endocrine imbalance. Hopkins S Nurs Mirror; 1981 Mar; 152(12):38. PubMed ID: 6908001 [No Abstract] [Full Text] [Related]
31. Further experiences with low doses of bromocriptine in Parkinson's disease. Fahn S; Côté LJ; Barrett RE; Snider SR Adv Biochem Psychopharmacol; 1980; 23():255-60. PubMed ID: 7395615 [No Abstract] [Full Text] [Related]
32. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis. Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626 [TBL] [Abstract][Full Text] [Related]
33. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. Im JH; Ha JH; Cho IS; Lee MC J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999 [TBL] [Abstract][Full Text] [Related]
34. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413 [TBL] [Abstract][Full Text] [Related]
35. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Factor SA; Weiner WJ Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289 [TBL] [Abstract][Full Text] [Related]
36. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease]. de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286 [TBL] [Abstract][Full Text] [Related]
37. [Bromocriptine - various pharmacological properties and indications for use]. Jeske W Pol Tyg Lek; 1982 Jul; 37(22):653-6. PubMed ID: 7177958 [No Abstract] [Full Text] [Related]
38. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ; Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806 [TBL] [Abstract][Full Text] [Related]
39. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease. Anglès A; Bagheri H; Saivin S; Montastruc JL Therapie; 2002; 57(4):408-10. PubMed ID: 12422563 [No Abstract] [Full Text] [Related]